Oncternal Therapeutics's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Oncternal Therapeutics (NASDAQ:ONCT) is scheduled to release its quarterly earnings report on March 7, 2024, with an expected EPS of $-3.07. Historical data shows a mixed reaction to past earnings, with the stock price fluctuating based on actual EPS outcomes and guidance provided. The company's stock has declined by 44.52% over the last year, indicating a bearish sentiment among long-term shareholders.
March 06, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oncternal Therapeutics is expected to report an EPS of $-3.07 for the upcoming earnings, with historical performance showing sensitivity to earnings outcomes and guidance. The stock has seen a significant decline over the past year.
Given the expected EPS and historical performance, the short-term impact on ONCT's stock price could be neutral to slightly negative. The stock's reaction will likely hinge on whether the actual earnings beat or miss expectations and the forward guidance provided. The long-term bearish trend and previous price reactions to earnings announcements suggest a cautious outlook, but without specific forward-looking statements or significant deviations from expectations, a dramatic move is less certain.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100